Skip to main content

Ivonescimab Overview

Ivonescimab
Ivonescimab Mechanism of action (for Illustrative Purposes Only)

Cooperative Binding Offers Potential to Drive Synergistic Anti-Tumor Activity

MOA schema
VEGF icon VEGF Dimer T Cell icon PD-1 Receptor in T Cell
Images for illustrative purposes only.

Dual Blocking of PD-1 & VEGF1

Increased Avidity in TME1

VEGF-A efficiently enhances the binding affinity to PD-1 by several fold

Enhanced Activity of T Cells1

VEGF dimer leads to potential interconnection of ivonescimab molecules, which may increase activity of T cells

T1/2 ~10 days2 and Fc-null region1

Could potentially lead to a favorable safety profile

*in vitro

Clinical Trials

For additional information on the HARMONi, HARMONi-3 or HARMONi-7 clinical trials, please visit clinicaltrials.gov (opens in new window) or submit a medical information request at smmttx.com/clinical-trials/med-info-request/


Phase 3 Study: NCT06396065 (opens in new window)3

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment.
Learn more (opens in new window).

HARMONi Fact Sheet (opens in new window)

Phase 3 Study: NCT05899608 (opens in new window)4

A Randomized, Double-blinded, Multiregional Phase 3 Study of ivonescimab Combined with Chemotherapy versus pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer.
Learn more (opens in new window).

HARMONi-3 Fact Sheet (opens in new window)

Phase 3 Study: NCT06767514 (opens in new window)5

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression.
Learn more (opens in new window).

HARMONi-7 Fact Sheet (opens in new window)

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”).

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

Abbreviations: EGFR mutant, epidermal growth factor receptor mutation; EGFR-TKI, epidermal growth factor receptor- tyrosine kinase inhibitor; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; T1/2=Half Life; TME, tumor microenvironment; VEGF, vascular endothelial growth factor.

References:

  1. Zhong T, et al. iScience. 2024;28(3):111722.
  2. Data on File 39. Summit Therapeutcs Inc.
  3. Goldman J, Passaro A, Laskin J, et al. Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi. Presented at WCLC 2025; September 6-9, 2025; Barcelona, Spain.
  4. Zhang J, Cai J, Wang H, et al. A Randomized Phase 3 Study of Ivonescimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer: HARMONi-3. Presented at ASCO 2025; May 30 - June 3, 2025; Chicago, IL.
  5. Passaro A, Girard N, Rodriguez-Abreu D, et al. A Randomized Phase 3 Study of Ivonescimab Versus Pembrolizumab as First-Line Treatment of Metastatic Non–Small Cell Lung Cancer With High Tumor PD-L1 Expression: HARMONi-7. Presented at ELCC 2025; March 26-29, 2025; Paris, France.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's NMPA.

Sign Up for Updates

For further information on how we protect your information, please refer to our Privacy Policy.

*Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

© Summit Therapeutics Inc.

Trademarks, Registered or Otherwise, are the property of their respective owner(s).